PUBLISHER: The Business Research Company | PRODUCT CODE: 1413939
PUBLISHER: The Business Research Company | PRODUCT CODE: 1413939
“ACE Inhibitors Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ace inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for ace inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The ace inhibitors market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.
ACE inhibitors, or angiotensin-converting enzyme inhibitors, constitute a class of medications utilized for the treatment and management of hypertension. Their mechanism of action involves the inhibition of the body's production of angiotensin II, a chemical responsible for constricting blood vessels and raising blood pressure. The primary purpose of ACE inhibitors is to induce relaxation in veins and arteries, ultimately leading to a reduction in blood pressure.
The main categories of ACE inhibitors encompass sulfhydryl-containing agents, dicarboxylate-containing agents, and phosphonate-containing agents. Sulfhydryl-containing agents are compounds characterized by the presence of a sulfhydryl group (-SH) in their structure. Various drugs fall into this category, including ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. These medications are available in diverse dosage forms, such as oral tablets and oral solutions. They find application in the treatment of various conditions, including heart failure, chronic kidney disease, hypertension, diabetes, and heart attacks. These medications are utilized by a range of end-users, including hospitals and online drug stores.
The countries covered in the ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The ace inhibitors market size has grown steadily in recent years. It will grow from $6.9 billion in 2023 to $7.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The observed growth in the historical period can be attributed to various factors. These include the heightened incidence of cardiovascular diseases, a growing aging population, the clinical effectiveness, and safety profile of medical interventions, the prevalence of diabetes, and the influence of regulatory endorsements and guidelines.
The ace inhibitors market size is expected to see strong growth in the next few years. It will grow to $9 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The expected growth in the forecast period is linked to several factors, notably the escalating global burden of cardiovascular diseases, the broadening scope of hypertension treatment guidelines, advancements in combination therapies, an increased focus on heart failure management, and improved awareness and access to healthcare. Key trends anticipated in the forecast period encompass a heightened emphasis on kidney protection, a preference for renin-angiotensin system inhibitors, challenges associated with generic competition and pricing pressures, a shift toward patient-centric approaches in healthcare, and the influence of regulatory updates and safety considerations.
The escalating prevalence of hypertension disorders is anticipated to play a pivotal role in driving the growth of the ACE inhibitors market. Hypertension, or high blood pressure, is characterized by elevated pressure within the blood vessels. ACE inhibitors, belonging to the category of angiotensin-converting enzyme inhibitors, represent a group of medications employed for the treatment and management of hypertension. These medications operate by relaxing blood vessels, leading to a reduction in blood pressure and an enhancement in blood flow. As of March 2023, the World Health Organization reported that an estimated 1.28 billion adults aged 30 to 79 worldwide were affected by hypertension, with two-thirds of these individuals residing in low- and middle-income nations. Over the past three decades, there has been a substantial increase of 650 million people aged 30 to 79 with hypertension. Alarmingly, around 46% of adults with hypertension are unaware of their condition due to a lack of diagnosis. This surge in hypertension cases stands as a significant factor propelling the growth of the ACE inhibitors market.
The rising incidence of cardiac disorders is another critical factor expected to contribute to the expansion of the ACE inhibitors market. Cardiac disorders encompass a range of medical conditions affecting the heart or blood vessels, including coronary artery disease, heart failure, and arrhythmias. ACE inhibitors play a crucial role in managing cardiac disorders by inhibiting the angiotensin-converting enzyme, resulting in reduced vasoconstriction, sodium retention, and aldosterone secretion, ultimately improving cardiac function. For instance, in May 2023, the Centers for Disease Control and Prevention reported that coronary artery disease (CAD) was responsible for 375,476 deaths in 2021, with approximately 1 in 20 adults aged 20 and older being affected by CAD. Notably, about 2 in 10 deaths from CAD occurred in adults less than 65 years old. The increasing incidence of cardiac disorders is thus a substantial driver behind the growth of the ACE inhibitors market.
A notable trend with a strong emphasis on product innovations, as major companies strategically develop novel products to strengthen their market positions and gain a competitive advantage. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, achieved FDA approval for FILSPARI (sparsentan). This groundbreaking non-immunosuppressive therapy is intended for use in patients with IgA nephropathy (IgAN). FILSPARI represents a significant advancement as the only approved non-immunosuppressive therapy. It is an oral medication designed for once-daily use by adults with primary IgAN who are at risk of rapid disease progression, typically presenting with a UPCR of less than 1.5 g/g and proteinuria. This approval marks a noteworthy milestone in treatment options for IgAN, supplementing traditional approaches involving systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, including angiotensin-receptor blockers (ARBs).
Major players in the ACE inhibitors market are further intensifying their efforts to introduce innovative drugs, as illustrated by the launch of a generic version of Capoten. Capoten is an ACE inhibitor containing the active ingredient captopril. In November 2021, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, introduced the generic version known as Captopril. This medication is prescribed for conditions such as hypertension, congestive heart failure, kidney problems caused by diabetes, and to improve survival after a heart attack. Captopril is available in various dosage strengths (12.5 mg, 25 mg, 50 mg, and 100 mg) and is packaged in 100-count bottles.
In January 2023, AstraZeneca, a UK-based pharmaceutical company, made a significant acquisition by purchasing CinCor Pharma for $1.3 billion. This strategic move positions AstraZeneca to expand its product line of aldosterone synthase inhibitors (ASI), particularly for blood pressure lowering in the treatment of resistant hypertension. CinCor Pharma, a US-based clinical-stage biopharmaceutical company, specializes in developing novel treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. This acquisition aligns with AstraZeneca's overarching goal of diversifying its portfolio and addressing critical medical needs in the cardiovascular therapeutic area.
Major companies operating in the ace inhibitors market report are Pfizer Inc.,Novartis AG,Johnson & Johnson Private Limited, Merck KGaA,Sanofi S.A.,Bayer AG,United Therapeutics Corporation,Teva Pharmaceutical Industries Ltd.,Bristol-Myers Squibb Co.,Takeda Pharmaceuticals Company,Daiichi Sankyo Company Ltd.,UCB Schwarz Pharma Inc.,Solvay Pharmaceuticals B.V.,Endo International plc,Otto Brandes GmbH,Sun Pharmaceutical Industries Ltd.,Boehringer Ingelheim,Bausch Health Companies Inc.,Dr. Reddy's Laboratories,Abbott Laboratories,Eli Lilly and Company,Cipla Limited, GlaxoSmithKline plc,Cadila Healthcare Limited,AbbVie Inc., Mylan N.V., Sandoz Group AG,Accord Healthcare Ltd.,AstraZeneca plc,Lupin Limited,Macleods Pharmaceuticals Limited,Zydus lifescience Ltd.,Apotex Inc.
North America was the largest region in the ACE inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the ace inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The global ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.